Testing for genetic alterations has become an important step in the treatment of patients with ovarian cancer. Although much has been achieved, says Mike Janicek, MD, there needs to be more widespread use of genetic testing in order to push the field forward.
For several decades, the systemic treatment of ovarian cancer has involved chemotherapy, with the relatively recent addition of anti-angiogenic strategies given with chemotherapy and in the maintenance setting. In the past decade, numerous poly(ADP-ribose) polymerase (PARP)-inhibiting agents have been assessed.
Cancer cells constantly grow and divide, which means that they need a consistent energy supply. A new study looks at how cancer derives fuel from fat cells and finds a potential mechanism to starve the tumor of its nutrition.
Visitors who walk into Deborah Giannecchini's ranch house in Modesto, California, will notice a well-tended garden, four small dogs who greet every visitor with enthusiasm and a sign that hangs prominently displayed in her living room that reads "It's never too late to live happily ever after."
Adding the monoclonal antibody drug trastuzumab—already used to treat certain breast cancers—to the chemotherapy regimen of women with a rare form of uterine cancer lengthens the amount of time their tumors are kept from growing, according to Johns Hopkins Medicine researchers conducting a small phase II trial of the regimen, testing its safety and value.
Traditionally, doctors have looked at where a cancer is coming from — lung, bowel, uterus, and so on — to target therapy. But, a new approach has come about in the last few years with medicines called immunotherapy.
Breast cancer is the most common invasive cancer in women, and the second main cause of cancer death in women, after lung cancer. In this article I will build a WideResNet based neural network to categorize slide images into two classes, one that contains breast cancer and other that doesn’t using Deep Learning Studio